Weekly Investment Analysts’ Ratings Updates for Illumina (ILMN)

A number of firms have modified their ratings and price targets on shares of Illumina (NASDAQ: ILMN) recently:

• 10/19/2026 – Illumina had its price target raised by Canaccord Genuity Group Inc. from $205.00 to $300.00. They now have a “hold” rating on the stock.
• 10/13/2026 – Illumina had its price target raised by TD Cowen from $210.00 to $270.00. They now have a “hold” rating on the stock.
• 10/11/2026 – Illumina was upgraded by Wall Street Zen from “hold” to “buy”.
• 10/7/2026 – Illumina had its price target raised by Barclays PLC from $160.00 to $200.00. They now have an “underweight” rating on the stock.
• 10/5/2026 – Illumina had its price target raised by Royal Bank Of Canada from $230.00 to $310.00. They now have an “outperform” rating on the stock.
• 10/3/2026 – Illumina was downgraded by Wall Street Zen from “buy” to “hold”.
• 10/1/2026 – Illumina had its price target raised by Guggenheim from $226.00 to $305.00. They now have a “buy” rating on the stock.
• 9/29/2026 – Illumina had its price target raised by Leerink Partners from $220.00 to $300.00. They now have an “outperform” rating on the stock.
• 9/28/2026 – Illumina had its price target raised by Piper Sandler from $225.00 to $305.00. They now have an “overweight” rating on the stock.
• 9/9/2026 – Illumina was upgraded by UBS Group AG from “neutral” to “buy”. They now have a $260.00 price target on the stock, up from $135.00.
• 9/3/2026 – Illumina had its price target raised by Argus from $180.00 to $235.00. They now have a “buy” rating on the stock.
• 9/1/2026 – Illumina was downgraded by Zacks Research from “strong-buy” to “hold”.
• 8/31/2026 – Illumina had its “hold (c)” rating reaffirmed by Weiss Ratings.

Insider Transactions at Illumina

In related news, SVP Christensen Wedel sold 1,033 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $191.52, for a total transaction of $197,840.16. Following the transaction, the senior vice president owned 14,023 shares in the company, valued at $2,685,684.96. This trade represents a 6.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith Meister sold 119,501 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total value of $26,099,018.40. Following the transaction, the director owned 770,350 shares in the company, valued at $168,244,440. This represents a 13.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 2,061,850 shares of company stock valued at $436,479,102. Insiders own 2.90% of the company’s stock.

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.